Volume 152, Issue 6, Pages 1310-1318.e1 (May 2017) Doppler Endoscopic Probe Monitoring of Blood Flow Improves Risk Stratification and Outcomes of Patients With Severe Nonvariceal Upper Gastrointestinal Hemorrhage  Dennis M. Jensen, Thomas O.G. Kovacs, Gordon V. Ohning, Kevin Ghassemi, Gustavo A. Machicado, Gareth S. Dulai, Alireza Sedarat, Rome Jutabha, Jeffrey Gornbein  Gastroenterology  Volume 152, Issue 6, Pages 1310-1318.e1 (May 2017) DOI: 10.1053/j.gastro.2017.01.042 Copyright © 2017 AGA Institute Terms and Conditions

Figure 1 Proportion of patients without rebleeding (rebleed free) during the 30 days after randomization. Top curve: Doppler patients, lower curve: standard treated patients. Product limit plots, compared by log-rank test: P = .0174. Gastroenterology 2017 152, 1310-1318.e1DOI: (10.1053/j.gastro.2017.01.042) Copyright © 2017 AGA Institute Terms and Conditions

Supplementary Figure 1 CONSORT diagram of Doppler endoscopic probe randomized controlled trial. *The specific reasons were mesalamine or very poor prognosis: 30-day survival not expected including those without organ transplantation (176 patients); no consent for study including surrogate (110 patients); uncooperative, noncompliant, or unable to return for study follow-up evaluation (45 patients); refused to consent (32 patients); UGI malignancy (26 patients); hypotensive on pressors (17 patients); not severe enough hemorrhage (13 patients); or did not meet entry criteria. ∗∗These included esophageal varices or portal hypertensive lesions (87 patients) and no SRH or UGI lesions that did not meet endoscopic inclusion criteria (288 patients). Gastroenterology 2017 152, 1310-1318.e1DOI: (10.1053/j.gastro.2017.01.042) Copyright © 2017 AGA Institute Terms and Conditions